Rury Holman trained in medicine at the University of Bristol in the United Kingdom and was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998. He is the Director of the University of Oxford Diabetes Trials Unit (which he instituted in 1985), Honorary Consultant Physician to the University of Oxford NHS Hospitals Trust, and the founding Academic Chairman of the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM). He is a Fellow of the Academy of Medical Sciences, an NIHR Senior Investigator, and the Diabetes Theme Leader for the Oxford Biomedical Research Centre. He runs an active Translational Research Group undertaking academic-led early phase trials of novel therapeutic agents, new medical devices and complex interventions. He is also Joint Chair of EXSCEL and TECOS, and Chief Investigator of ACE and UKPDS.
Professor Holman divides his time between clinical care of patients, teaching and his many research interests. He has designed and run many multicentre studies that focus primarily on the prevention, appropriate treatment and cardiovascular risk reduction in people with type 2 diabetes or non-diabetic hyperglycaemia. He has received 14 national and international awards and published over 300 peer-reviewed papers with 13 that have been cited more than 1,000 times.
Dualities of Interest
Professor Holman has received grants and personal fees from Merck, grants from Bayer, and AstraZeneca, personal fees from Amgen, Bayer, Intarcia, Novartis, Novo Nordisk, and other support from GlaxoSmithKline, Janssen, and Takeda.